{"id":792,"date":"2026-09-01T17:35:05","date_gmt":"2026-09-01T17:35:05","guid":{"rendered":"https:\/\/nhdbio.com\/resources\/melanotan-ii-cyclic-peptide-identity-quality-guide\/"},"modified":"2026-09-08T07:30:41","modified_gmt":"2026-09-08T07:30:41","slug":"melanotan-ii-cyclic-peptide-identity-quality-guide","status":"publish","type":"post","link":"https:\/\/nhdbio.com\/fr\/melanotan-ii-cyclic-peptide-identity-quality-guide\/","title":{"rendered":"Guide d'identit\u00e9 Melanotan II\u00a0: S\u00e9quence cyclique et risques li\u00e9s \u00e0 la qualit\u00e9"},"content":{"rendered":"

Melanotan II is a cyclic heptapeptide analogue of \u03b1-MSH. Its lactam ring, D-phenylalanine and terminal modifications are identity-defining.<\/p>

Evidence at a glance<\/h2>
  • PubChem lists formula C50H69N15O9, molecular weight 1024.2 g\/mol and CID 92432.<\/li>
  • The condensed sequence is Ac-Nle-Asp(1)-His-D-Phe-Arg-Trp-Lys(1)-NH2, with a side-chain lactam bridge.<\/li>
  • Regulator testing of online products found large between-bottle content differences, so appearance and label strength are not identity evidence.<\/li><\/ul><\/div><\/div>
    \"Documentary
    AI-generated editorial illustration illustrating an analytical workflow. It does not depict a supplied product, released lot, approved formulation or assay result.<\/figcaption><\/figure>

    Identity record<\/h2>

    A linear peptide with the same residue list is not Melanotan II. Ring closure changes mass, conformation and chromatographic behavior; stereochemistry at D-Phe also needs to match the reference.<\/p>

    Sequence<\/strong>Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2<\/span><\/div>
    Formula and mass<\/strong>C50H69N15O9; 1024.2 g\/mol<\/span><\/div>
    PubChem<\/strong>CID 92432<\/span><\/div>
    Critical features<\/strong>N-acetylation, norleucine, D-Phe, lactam closure and C-terminal amide<\/span><\/div>
    Core tests<\/strong>Intact mass, peptide mapping, ring\/sequence evidence, purity, content and aggregation<\/span><\/div><\/div><\/div>

    Analytical and evidence boundary<\/h2>

    Peptide-related impurities and aggregation can create immunogenicity concerns for some routes. FDA\u2019s compounding safety page explicitly identifies these concerns for Melanotan II.<\/p>

    Do not use \u201ctanning peptide\u201d as if it were an approved indication. The FDA record describes Melanotan II as an unapproved new drug, and research-use copy should not provide consumer administration guidance.<\/p>

    Editorial rule<\/h2>

    State the exact material, form, model or population and endpoint supported by the cited record. Do not convert mechanistic plausibility, an animal result, an official finished-drug label or an analytical test into a claim about an unrelated catalog lot.<\/p>","protected":false},"excerpt":{"rendered":"

    Melanotan II est un analogue heptapeptidique cyclique de l'\u03b1-MSH. Son cycle lactame, la D-ph\u00e9nylalanine et ses modifications terminales d\u00e9finissent son identit\u00e9.<\/p>","protected":false},"author":1,"featured_media":776,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"pim_family_ids":"350","pim_article_type":"Evidence and material-quality guide","pim_evidence_level":"PubChem identity, primary human exposure and regulator-tested product data","pim_reviewer":"Site evidence editorial team","pim_reviewed_date":"2026-09-02","pim_editorial_note":"Source-checked on 2026-09-02. Null results, sample size, model\/population limits and regulatory scope are retained. This is not medical advice, a customer case or validation of a catalog lot.","pim_review_status":"reviewed","pim_review_reason":"Primary and official sources, numerical results, null findings, limitations, product-evidence boundary and image disclosure checked for batch 4.","pim_creation_method":"This article discusses the source records listed below, with the study models and limitations stated alongside the findings. AI-assisted drafting and image generation were used. The reference list identifies the records behind this article; it is not an independent peer review or verification of a supplied catalog lot.","pim_sources":"[{\"title\":\"Melanotan II pilot phase I study\",\"url\":\"https:\/\/pubmed.ncbi.nlm.nih.gov\/8637402\/\",\"note\":\"Three-person single-blind pilot; PMID 8637402.\"},{\"title\":\"Melanotan II systemic toxicity and rhabdomyolysis\",\"url\":\"https:\/\/pubmed.ncbi.nlm.nih.gov\/23121206\/\",\"note\":\"Mass-spectrometry-confirmed case report; PMID 23121206.\"},{\"title\":\"TGA finds inconsistent Melanotan II content\",\"url\":\"https:\/\/www.tga.gov.au\/safety\/safety-monitoring-and-information\/safety-alerts\/melanotan-ii-tanning-peptide-products-found-be-inconsistently-dosed\",\"note\":\"Official August 2026 laboratory-testing safety alert.\"},{\"title\":\"FDA Melanotan II enforcement record\",\"url\":\"https:\/\/www.fda.gov\/regulatory-information\/electronic-reading-room\/notice-opportunity-hearing-nooh-manookian-edward-8516\",\"note\":\"Official record describing Melanotan II as an unapproved new drug.\"},{\"title\":\"PubChem Melanotan II record\",\"url\":\"https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/melanotan-II\",\"note\":\"Cyclic sequence, formula and molecular weight; CID 92432.\"}]","footnotes":""},"categories":[20],"tags":[],"class_list":["post-792","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-evidence-quality-guides"],"yoast_head":"\nMelanotan II Identity Guide: Cyclic Sequence and Quality Risks<\/title>\n<meta name=\"description\" content=\"Melanotan II is a cyclic heptapeptide analogue of \u03b1-MSH. Its lactam ring, D-phenylalanine and terminal modifications are identity-defining.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nhdbio.com\/fr\/melanotan-ii-cyclic-peptide-identity-quality-guide\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Melanotan II Identity Guide: Cyclic Sequence and Quality Risks\" \/>\n<meta property=\"og:description\" content=\"Melanotan II is a cyclic heptapeptide analogue of \u03b1-MSH. Its lactam ring, D-phenylalanine and terminal modifications are identity-defining.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nhdbio.com\/fr\/melanotan-ii-cyclic-peptide-identity-quality-guide\/\" \/>\n<meta property=\"og:site_name\" content=\"NHD\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-01T17:35:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-08T07:30:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/melanotan-ii-quality.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1672\" \/>\n\t<meta property=\"og:image:height\" content=\"941\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"NHD Technical Team\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Peptide Raw Materials and Custom Peptide Synthesis\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"NHD Technical Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/melanotan-ii-cyclic-peptide-identity-quality-guide\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/melanotan-ii-cyclic-peptide-identity-quality-guide\\\/\"},\"author\":{\"name\":\"NHD Technical Team\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\"},\"headline\":\"Melanotan II Identity Guide: Cyclic Sequence and Quality Risks\",\"datePublished\":\"2026-09-01T17:35:05+00:00\",\"dateModified\":\"2026-09-08T07:30:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/melanotan-ii-cyclic-peptide-identity-quality-guide\\\/\"},\"wordCount\":265,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/melanotan-ii-cyclic-peptide-identity-quality-guide\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/melanotan-ii-quality.webp\",\"articleSection\":[\"Evidence & Quality Guides\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/melanotan-ii-cyclic-peptide-identity-quality-guide\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/melanotan-ii-cyclic-peptide-identity-quality-guide\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/melanotan-ii-cyclic-peptide-identity-quality-guide\\\/\",\"name\":\"Melanotan II Identity Guide: Cyclic Sequence and Quality Risks\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/melanotan-ii-cyclic-peptide-identity-quality-guide\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/melanotan-ii-cyclic-peptide-identity-quality-guide\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/melanotan-ii-quality.webp\",\"datePublished\":\"2026-09-01T17:35:05+00:00\",\"dateModified\":\"2026-09-08T07:30:41+00:00\",\"description\":\"Melanotan II is a cyclic heptapeptide analogue of \u03b1-MSH. Its lactam ring, D-phenylalanine and terminal modifications are identity-defining.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/melanotan-ii-cyclic-peptide-identity-quality-guide\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/melanotan-ii-cyclic-peptide-identity-quality-guide\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/melanotan-ii-cyclic-peptide-identity-quality-guide\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/melanotan-ii-quality.webp\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/melanotan-ii-quality.webp\",\"width\":1672,\"height\":941,\"caption\":\"AI-generated illustration: cyclic-peptide quality-control bench\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/melanotan-ii-cyclic-peptide-identity-quality-guide\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Melanotan II Identity Guide: Cyclic Sequence and Quality Risks\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"name\":\"NHD\",\"description\":\"Peptide Raw Materials and Custom Peptide Synthesis\",\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nhdbio.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\",\"name\":\"NHD\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"width\":2172,\"height\":724,\"caption\":\"NHD\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\",\"name\":\"NHD Technical Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"caption\":\"NHD Technical Team\"},\"description\":\"NHD Technical Team maintains research-use catalog documentation and evidence summaries. Reviewed articles link to peer-reviewed papers, trial registries and regulatory records, retain null findings and study limitations, and distinguish published interventions from catalog materials. AI-assisted drafting may be used for structure; source links and evidence boundaries remain visible. This work is not independent peer review or medical advice.\",\"sameAs\":[\"https:\\\/\\\/nhdbio.com\"],\"url\":\"https:\\\/\\\/nhdbio.com\\\/fr\\\/author\\\/qianmiao-technical-team\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Guide d'identit\u00e9 Melanotan II\u00a0: S\u00e9quence cyclique et risques li\u00e9s \u00e0 la qualit\u00e9","description":"Melanotan II est un analogue heptapeptidique cyclique de l'\u03b1-MSH. Son cycle lactame, la D-ph\u00e9nylalanine et ses modifications terminales d\u00e9finissent son identit\u00e9.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nhdbio.com\/fr\/melanotan-ii-cyclic-peptide-identity-quality-guide\/","og_locale":"fr_FR","og_type":"article","og_title":"Melanotan II Identity Guide: Cyclic Sequence and Quality Risks","og_description":"Melanotan II is a cyclic heptapeptide analogue of \u03b1-MSH. Its lactam ring, D-phenylalanine and terminal modifications are identity-defining.","og_url":"https:\/\/nhdbio.com\/fr\/melanotan-ii-cyclic-peptide-identity-quality-guide\/","og_site_name":"NHD","article_published_time":"2026-09-01T17:35:05+00:00","article_modified_time":"2026-09-08T07:30:41+00:00","og_image":[{"width":1672,"height":941,"url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/melanotan-ii-quality.webp","type":"image\/webp"}],"author":"NHD Technical Team","twitter_card":"summary_large_image","twitter_description":"Peptide Raw Materials and Custom Peptide Synthesis","twitter_misc":{"\u00c9crit par":"NHD Technical Team","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nhdbio.com\/melanotan-ii-cyclic-peptide-identity-quality-guide\/#article","isPartOf":{"@id":"https:\/\/nhdbio.com\/melanotan-ii-cyclic-peptide-identity-quality-guide\/"},"author":{"name":"NHD Technical Team","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1"},"headline":"Melanotan II Identity Guide: Cyclic Sequence and Quality Risks","datePublished":"2026-09-01T17:35:05+00:00","dateModified":"2026-09-08T07:30:41+00:00","mainEntityOfPage":{"@id":"https:\/\/nhdbio.com\/melanotan-ii-cyclic-peptide-identity-quality-guide\/"},"wordCount":265,"commentCount":0,"publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"image":{"@id":"https:\/\/nhdbio.com\/melanotan-ii-cyclic-peptide-identity-quality-guide\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/melanotan-ii-quality.webp","articleSection":["Evidence & Quality Guides"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/nhdbio.com\/melanotan-ii-cyclic-peptide-identity-quality-guide\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/nhdbio.com\/melanotan-ii-cyclic-peptide-identity-quality-guide\/","url":"https:\/\/nhdbio.com\/melanotan-ii-cyclic-peptide-identity-quality-guide\/","name":"Guide d'identit\u00e9 Melanotan II\u00a0: S\u00e9quence cyclique et risques li\u00e9s \u00e0 la qualit\u00e9","isPartOf":{"@id":"https:\/\/nhdbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nhdbio.com\/melanotan-ii-cyclic-peptide-identity-quality-guide\/#primaryimage"},"image":{"@id":"https:\/\/nhdbio.com\/melanotan-ii-cyclic-peptide-identity-quality-guide\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/melanotan-ii-quality.webp","datePublished":"2026-09-01T17:35:05+00:00","dateModified":"2026-09-08T07:30:41+00:00","description":"Melanotan II est un analogue heptapeptidique cyclique de l'\u03b1-MSH. Son cycle lactame, la D-ph\u00e9nylalanine et ses modifications terminales d\u00e9finissent son identit\u00e9.","breadcrumb":{"@id":"https:\/\/nhdbio.com\/melanotan-ii-cyclic-peptide-identity-quality-guide\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nhdbio.com\/melanotan-ii-cyclic-peptide-identity-quality-guide\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/nhdbio.com\/melanotan-ii-cyclic-peptide-identity-quality-guide\/#primaryimage","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/melanotan-ii-quality.webp","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/melanotan-ii-quality.webp","width":1672,"height":941,"caption":"AI-generated illustration: cyclic-peptide quality-control bench"},{"@type":"BreadcrumbList","@id":"https:\/\/nhdbio.com\/melanotan-ii-cyclic-peptide-identity-quality-guide\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nhdbio.com\/"},{"@type":"ListItem","position":2,"name":"Melanotan II Identity Guide: Cyclic Sequence and Quality Risks"}]},{"@type":"WebSite","@id":"https:\/\/nhdbio.com\/#website","url":"https:\/\/nhdbio.com\/","name":"NHD","description":"Mati\u00e8res premi\u00e8res peptidiques et synth\u00e8se sur mesure","publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nhdbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/nhdbio.com\/#organization","name":"NHD","url":"https:\/\/nhdbio.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","width":2172,"height":724,"caption":"NHD"},"image":{"@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1","name":"\u00c9quipe technique NHD","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","caption":"NHD Technical Team"},"description":"L'\u00e9quipe technique NHD maintient la documentation du catalogue d'utilisation de la recherche et les r\u00e9sum\u00e9s des preuves. Les articles examin\u00e9s renvoient \u00e0 des articles \u00e9valu\u00e9s par des pairs, \u00e0 des registres d'essais et \u00e0 des dossiers r\u00e9glementaires, conservent les r\u00e9sultats nuls et les limites des \u00e9tudes, et distinguent les interventions publi\u00e9es des documents du catalogue. Le dessin assist\u00e9 par AI peut \u00eatre utilis\u00e9 pour la structure\u00a0; les liens vers les sources et les limites des preuves restent visibles. Ce travail ne constitue pas un examen ind\u00e9pendant par des pairs ni un avis m\u00e9dical.","sameAs":["https:\/\/nhdbio.com"],"url":"https:\/\/nhdbio.com\/fr\/author\/qianmiao-technical-team\/"}]}},"_links":{"self":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/posts\/792","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/comments?post=792"}],"version-history":[{"count":1,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/posts\/792\/revisions"}],"predecessor-version":[{"id":1195,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/posts\/792\/revisions\/1195"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/media\/776"}],"wp:attachment":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/media?parent=792"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/categories?post=792"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/tags?post=792"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}